Intercept Pharmaceuticals (ICPT)

Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the Saber Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the Oradur sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the Transdur transdermal patch technology, the Durin Biodegradable Implant (drug-loaded implant system) and the Microdur Biodegradable Microparticulates (microspheres injectable system). DRRX also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DRRX has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners. DRRX is also developing DUR-928, an endogenous orally bioavailable small molecule that modulates the activity of various nuclear receptors that play an important regulatory role in lipid homeostasis, inflammation and cell survival.

ICPT 4Q18 rev
ICPT Regenerate interim look rev
ICPT Regenerate update rev
ICPT 3Q18 rev
ICPT-2Q18-rev.pdf
ICPT 1Q18 rev
ICPT 1Q18 guidance rev
ICPT 4Q17 rev
ICPT 3Q17 rev
ICPT FDA rev
ICPT 2Q17 rev
ICPT 1Q17 rev
ICPT 4Q16 rev (1)
ICPT REGENERATE update 2.10.17 rev (2)
icpt-3q16-jfm-edits-rev
ICPT.2Q16 rev
ICPT.Ocaliva approval.5.31.16 rev
ICPT 1Q16 rev
ICPT.AdCom.4.7.16 rev
ICPT 4Q15 rev
ICPT 3Q15_JFM rev
ICPT AASLD 2015 rev
ICPT initiation of Coverage final.8.31.15